Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | TOP2A | P11388 | 15/20 | 0.53 |
| ▸ | TOP1 | P11387 | 3/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011751 | 0.95 | CYP3A4 (0.65) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7004810 | 0.94 | CYP3A4 (0.68) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7003705 | 0.94 | CYP3A4 (0.68) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL8479016 | 0.93 | ALDH1A1 (0.69) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7010026 | 0.93 | ALDH1A1 (0.69) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7004969 | 0.93 | ALDH1A1 (0.69) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7008772 | 0.93 | CYP3A4 (0.61) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7012483 | 0.92 | CYP3A4 (0.66) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7013849 | 0.92 | CYP3A4 (0.66) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL7009205 | 0.92 | CYP3A4 (0.60) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-6136823-A | BACTERICIDES OR VIRICIDES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-5994575-A | Phenylenediamines and process for preparing the same | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0897909-A1 | NOVEL PHENYLENEDIAMINES AND PROCESS FOR PREPARING THE SAME | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-02-24 | — | — | EP | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | CYP3A4 3514/4885CYP2C9 154/4885ALDH1A1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.